415 provides seed funding for and advises (primarily early stage) companies. 415 assists in the areas of strategy, funding.
415 provides seed funding for and advises (primarily early stage) companies. 415 assists in the areas of strategy, funding.
Key people at 415.
Key people at 415.
415 Capital is a specialist venture capital firm dedicated to investing in breakthrough medical innovations, with a strong focus on early- and development-stage MedTech companies. Their mission centers on supporting life-saving technologies—particularly in the cardiovascular space, the leading cause of death globally. The firm’s investment philosophy emphasizes backing pioneering startups that address unmet clinical needs, especially in medical devices for cardiovascular disease and its comorbidities. 415 Capital primarily targets seed and early-stage companies, providing not only capital but also strategic guidance and operational support. Their sector focus is tightly aligned with MedTech, and their impact is evident in the growth and successful exits of over 50 MedTech startups, helping shape the European and global healthcare innovation ecosystem.
Founded in 2018 and headquartered in Munich, Germany, 415 Capital was established by a team of seasoned investors and entrepreneurs with deep roots in the MedTech industry. Key partners include Frank Groenewegen, David Thompson, and Frederik Groenewegen, all of whom have extensive experience in founding, building, and exiting MedTech companies. The firm evolved from decades of hands-on involvement in the sector, leveraging their collective expertise to create a venture capital platform tailored to the unique challenges and opportunities of early-stage MedTech innovation. Their focus on cardiovascular technologies emerged from both market need and personal experience, positioning 415 Capital as a go-to partner for startups tackling some of healthcare’s most pressing problems.
415 Capital is riding the wave of digital health and MedTech innovation, a sector experiencing rapid growth due to aging populations, rising healthcare costs, and advances in medical technology. The timing is particularly favorable as cardiovascular disease remains a dominant global health challenge, driving demand for novel solutions. The firm’s focus on early-stage companies aligns with the broader trend of venture capital moving deeper into specialized healthcare verticals, where deep domain expertise is essential. By nurturing startups at the earliest stages, 415 Capital helps accelerate the translation of scientific breakthroughs into real-world therapies, influencing the trajectory of medical innovation and improving patient outcomes worldwide.
Looking ahead, 415 Capital is well-positioned to continue shaping the MedTech landscape, especially as the demand for cardiovascular and digital health solutions intensifies. The firm’s blend of capital, expertise, and hands-on support will remain a critical asset for startups navigating the complex path from concept to commercialization. As healthcare systems increasingly prioritize innovation and efficiency, 415 Capital’s influence is likely to grow, both in terms of portfolio impact and ecosystem leadership. Their journey reflects the broader shift toward specialized, founder-friendly venture capital in healthcare—a trend that will define the next generation of medical breakthroughs.